When analyzing subgroups, no significant differences in efficacy were observed with respect to age, disease characteristics, bone marrow blast percentage, dose fractionization, or previous treatment. A significant correlation was observed with peripheral blood blast counts. In 19 patients with peripheral blood counts < 200/microliter, 8 responded (i.e., achieved one category of complete recovery as defined in advance). The correlation remained even when the endpoint was relaxed to included additional patients who had > 50% reduction in bone marrow blasts.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.